| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_872dd7cd609eb2a937dcfd303d521798 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 |
| filingDate |
2017-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_064130899e37864a8af5f2146968ddcc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_841e072428290ed482928a6217551551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_add3d421ec680a89fed5b2990f3428ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce409a7558cef66740826595f00daec4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe6455892e2ff87c35ddfbffe522d0a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de89badcca2ac09870b0828c4d015bd4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6a51614c77f85d3e36750e393332551 |
| publicationDate |
2022-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11254753-B2 |
| titleOfInvention |
Antibodies with reduced binding to process impurities |
| abstract |
The present invention relates to variant antibodies and methods of generating said antibodies with a reduced level of binding to process impurities. In particular, the invention describes variant IgG4 antibodies which have been modified in the heavy chain constant region at any one or a combination of amino acids in the region between Kabat residues 203 and 256, wherein the variant IgG4 antibody has a reduced level of binding to host cell protein (HCP), compared to an unmodified IgG4 antibody. The invention also relates to compositions comprising said variant IgG4 antibodies. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023168352-A1 |
| priorityDate |
2016-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |